Principal Investigator
Pasquale Benedetto
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20220922
Clinical Trial Summary
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Prostate, Bladder, and Kidney Cancers
Contact Information
Phone Number
305-243-2647